The 10 most recent market catalysts affecting $LEXX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Lexaria Bioscience shares are trading higher after the company announced an update on its financial position, showing cash on hand reaching ~$4.60 per share following $7.9 million in recent net proceeds.
This headline indicates a significant positive corporate catalyst for Lexaria Bioscience. The substantial increase in cash on hand, particularly when expressed on a per-share basis…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 75
Lexaria Bioscience Says Australian Tax Refund And Institutional Financing Priced At $12.92/Share Yielded $7.9M Net, About $4.60/Share In Cash On 2.1 Million Shares Outstanding; Says No Further Financings Planned In 2026
This headline is a significant positive catalyst for Lexaria Bioscience. The $7.9 million net proceeds, including a substantial Australian tax refund and institutional financing, p…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 75
Lexaria Bioscience shares are trading lower after the company announced a warrant inducement repricing of 453,969 warrants to $12.92 per share from the original prices of $17.85 to $45.90.
The repricing of warrants from a range of $17.85-$45.90 down to $12.92 per share is a highly dilutive event for existing Lexaria Bioscience shareholders. This action suggests the c…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 65
Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co.
Lexaria Bioscience announced that its wholly-owned Australian subsidiary, Lexaria (AU) Pty Ltd, received a cash rebate of AU$3,666,611.98 from the Australian Tax Office. This payme…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform
Lexaria Bioscience reported compelling results from its animal study, showing its DehydraTECH 3.0 platform significantly improved the oral bioavailability of Amycretin and Retatrut…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know
Lexaria Bioscience has entered into a Material Transfer Agreement with PegBio Ltd., a significant development for the company. Under this agreement, Lexaria will apply its patented…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Lexaria Bioscience shares are trading higher. The company announced a Material Transfer Agreement with Pegbio to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry.
This headline represents a significant corporate catalyst for Lexaria Bioscience. The Material Transfer Agreement with Pegbio, a company developing a molecule for the high-growth G…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 65
Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry
Lexaria Bioscience (LEXX) has signed an MTA with PegBio, a company with approved and pipeline GLP-1 drugs, to test Lexaria's DehydraTECH technology on PegBio's proprietary GLP-1 mo…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Lexaria Bioscience shares are trading lower after the company announced it intends to effect a reverse stock split of its common stock effective August 3.
A reverse stock split is almost universally viewed negatively by the market as it often indicates a company is struggling to maintain its stock price above minimum exchange require…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate
Lexaria Bioscience announced its Q3 earnings per share, reporting a loss of $(0.08), which was better than the analyst consensus estimate of $(0.09). This beat, while still a loss,…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.